Literature DB >> 32283215

False negative rate of COVID-19 is eliminated by using nasal swab test.

Chaojun Xie1, Jianyun Lu1, Di Wu1, Lin Zhang1, Hongjun Zhao2, Boqi Rao2, Zhicong Yang3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32283215      PMCID: PMC7151360          DOI: 10.1016/j.tmaid.2020.101668

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


× No keyword cloud information.
Dear Editor, Several studies of the new outbreak of COVID-19 patients on clinical, epidemiological, and radiological features have now published [1,2]. Apositive RT-PCR result of the discharged patients was reported by Lan et al. [3], we are now reporting the expanded population data of the re-positive patients in Guangzhou City, China. Collect the discharged COVID-19 patients' information from former epidemiological investigation of Guangzhou Center for Disease Control and Prevention. Data was included the date of onset, date of conformed diagnose, date of discharge, date of first sampling, and the date of the nucleic acid test returned positive. All the discharged patients were followed the criteria of: (a) temperature returned to normal more than 3 days later, (b) Disappearance of respiratory symptoms, (c) substantially improved acute exudative lesions on chest computed tomography (CT) images, and (d) two consecutive negative nucleic acid tests separated by at least 1 day [4]. A total of 161 discharged patients of COVID-19 in Guangzhou has retested for SARS-CoV-2, in which 22 patients whose nucleic acid tests were positive accounted for 13.66% (Table S1 in the Supplementary Appendix). As shown in Fig. 1 A, the median time interval between onset of symptom to nucleic acid test return positive after discharge was 26 days (range, 14 to 37; mean, 26.05), in which the longest infection period is 37 days that suggested that the current 14-day medical observation period may be insufficient and needs to be re-evaluated, and the median time interval between the discharge to nucleic acid test return positive was 7.5 days (range, 1 to 14; mean, 7.91) that indicated that the 14-day medical observation period after discharge is an essential measure for controlling epidemic spread.
Fig. 1

A) Time interval of every two time points among the four time points

Negative group: The median time interval between onset of symptom to diagnosis was 6 days (range,

2 to 17; mean, 6.52) and the median time interval between diagnosis to discharge was 12 days (range,

1 to 23; mean, 12.50). The median time interval between onset of symptom to discharge was 19 days (range, 5 to 31; mean, 19.01).

Positive group: The median time interval between onset of symptom to diagnosis was 5 days (range, 0 to 16; mean, 4.45). a

nd the median time interval between diagnosis to discharge was 14.5 days (range, 6 to 20; mean, 13.68). The median time interval between onset of symptom to discharge was 19 days (range, 7 to 25; mean, 18.14) and the median time interval between onset of symptom to nucleic acid test turn positive after discharge (the last test was positive) was 26 days (range, 14 to 37; mean, 26.05). The median time interval between the discharge to nucleic acid test turn positive (the last test was positive) was 7.5 days (range, 1 to 14; mean, 7.91) and the median time interval between the diagnosis to nucleic acid test turn positive (the last test was positive) was 21 days (range, 13 to 29; mean, 21.61).

B) RT-PCR results of 22 cases.

A) Time interval of every two time points among the four time points Negative group: The median time interval between onset of symptom to diagnosis was 6 days (range, 2 to 17; mean, 6.52) and the median time interval between diagnosis to discharge was 12 days (range, 1 to 23; mean, 12.50). The median time interval between onset of symptom to discharge was 19 days (range, 5 to 31; mean, 19.01). Positive group: The median time interval between onset of symptom to diagnosis was 5 days (range, 0 to 16; mean, 4.45). a nd the median time interval between diagnosis to discharge was 14.5 days (range, 6 to 20; mean, 13.68). The median time interval between onset of symptom to discharge was 19 days (range, 7 to 25; mean, 18.14) and the median time interval between onset of symptom to nucleic acid test turn positive after discharge (the last test was positive) was 26 days (range, 14 to 37; mean, 26.05). The median time interval between the discharge to nucleic acid test turn positive (the last test was positive) was 7.5 days (range, 1 to 14; mean, 7.91) and the median time interval between the diagnosis to nucleic acid test turn positive (the last test was positive) was 21 days (range, 13 to 29; mean, 21.61). B) RT-PCR results of 22 cases. The key point that differed the sampling after discharge from the sampling before discharge only including throat swabs and anal swabs is that we increased sampling of nasal swabs. The emergence of 22 discharged patients of return positive suggested that medical institutions should reassess discharge standards and improve sampling methods and types. As listed in Fig. 1B, we selected 3 discharged patients to collect nasal swabs that all were detected to positive of SARS-CoV-2. Notably, there are two familial clustering cases in the “re-positive” patients. As previously reported by Zou LR et al. [5], higher viral loads were detected soon after symptom onset, with higher viral loads detected in the nose than in the throat, consequently we suggested that increase nasal swab sampling for SARS-Cov-2 test to reduce false negative rate of nucleic acid test. There were many kinds of specimens collected from one patient, but always only one specimen type was detected for positive of SARS-CoV-2, which indicated that specimen used for nucleic acid test should be collected from multiple body parts before discharge. There are 8 discharged patients tested positive only on the fourth test, including two tests before discharge and two tests after discharge, which shown that relatively high false negative rate was 36.4% (8/22) before the fourth test and suggested that increase the number of tests before discharge. The exact period of infection by far has not been determined, and the knowledge of epidemiological characteristics of COVID-19 were still insufficient so that we need to collect more information to explore.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of. Guangzhou Center for Disease Control and Prevention

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

General Guidance Project of Guangzhou Health and Family Planning Technology 20181A011050(C Xie), Health Industry Scientific Research Project of Gansu Province GSWSKY2018-18(H Zhao), and Grants 81803325(D Wu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions

HJ Zhao and ZC Yang designed this study. CJ Xie, JY Lu, D Wu, L Zhang collated the data, and HJ Zhao and ZC Yang discovered and analyzed relevance. ZC Yang and CJ Xie contributed to interpreting the results. HJ Zhao, BQ Rao wrote the manuscript and analyzed the results. ZC Yang revised the manuscript. All authors read and approved the final manuscript.

Declaration of competing interest

None of the authors has any conflict of interest to declare.
  4 in total

1.  Positive RT-PCR Test Results in Patients Recovered From COVID-19.

Authors:  Lan Lan; Dan Xu; Guangming Ye; Chen Xia; Shaokang Wang; Yirong Li; Haibo Xu
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.

Authors:  Lirong Zou; Feng Ruan; Mingxing Huang; Lijun Liang; Huitao Huang; Zhongsi Hong; Jianxiang Yu; Min Kang; Yingchao Song; Jinyu Xia; Qianfang Guo; Tie Song; Jianfeng He; Hui-Ling Yen; Malik Peiris; Jie Wu
Journal:  N Engl J Med       Date:  2020-02-19       Impact factor: 91.245

4.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

  4 in total
  21 in total

1.  Universal screening for SARS-CoV-2 infection: a rapid review.

Authors:  Meera Viswanathan; Leila Kahwati; Beate Jahn; Kayla Giger; Andreea Iulia Dobrescu; Christine Hill; Irma Klerings; Jana Meixner; Emma Persad; Birgit Teufer; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2020-09-15

2.  Antibody tests for identification of current and past infection with SARS-CoV-2.

Authors:  Jonathan J Deeks; Jacqueline Dinnes; Yemisi Takwoingi; Clare Davenport; René Spijker; Sian Taylor-Phillips; Ada Adriano; Sophie Beese; Janine Dretzke; Lavinia Ferrante di Ruffano; Isobel M Harris; Malcolm J Price; Sabine Dittrich; Devy Emperador; Lotty Hooft; Mariska Mg Leeflang; Ann Van den Bruel
Journal:  Cochrane Database Syst Rev       Date:  2020-06-25

Review 3.  Reinfection or Reactivation of Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review.

Authors:  Xiujuan Tang; Salihu S Musa; Shi Zhao; Daihai He
Journal:  Front Public Health       Date:  2021-06-11

4.  Spinal anaesthesia and COVID-19 transmission to anaesthetists. Comment on Br J Anaesth 2020; 124: 670-5.

Authors:  Richard Smiley
Journal:  Br J Anaesth       Date:  2020-05-01       Impact factor: 9.166

5.  RNA conversion of COVID-19 in respiratory and alimentary specimens during asymptomatic convalescence.

Authors:  Yichi Zhang; Tingting Su; Bing Han; Miao Huang; Xueshi Zhou; Jian Wang; Yuanwang Qiu; Yingbin Liu; Jinyang Gu
Journal:  J Gastroenterol Hepatol       Date:  2020-06-26       Impact factor: 4.369

6.  The evidence of indirect transmission of SARS-CoV-2 reported in Guangzhou, China.

Authors:  Chaojun Xie; Hongjun Zhao; Kuibiao Li; Zhoubin Zhang; Xiaoxiao Lu; Huide Peng; Dahu Wang; Jin Chen; Xiao Zhang; Di Wu; Yuzhou Gu; Jun Yuan; Lin Zhang; Jiachun Lu
Journal:  BMC Public Health       Date:  2020-08-05       Impact factor: 3.295

7.  The dilemma of COVID-19 recurrence after clinical recovery.

Authors:  Marco Bongiovanni; Marco Vignati; Giuseppe Giuliani; Giampiero Manes; Stefania Arienti; Loris Pelucchi; Nicoletta Cattaneo; Bruno Dino Bodini; Danila Clerici; Fabio Rosa; Lucienne Pellegrini; Mario Schettino; Desiree Picascia; Francesco Bini
Journal:  J Infect       Date:  2020-08-15       Impact factor: 6.072

8.  Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19.

Authors:  Van T Hoang; Thi L Dao; Philippe Gautret
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

Review 9.  Coronavirus disease (COVID-19): An updated review based on current knowledge and existing literature for dermatologists.

Authors:  Ishmeet Kaur; Aseem Sharma; Deepak Jakhar; Anupam Das; Sujala Sacchidanand Aradhya; Rashmi Sharma; Veenu Jindal; Madhulika Mhatre
Journal:  Dermatol Ther       Date:  2020-06-26       Impact factor: 3.858

10.  Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis.

Authors:  Mahalul Azam; Rina Sulistiana; Martha Ratnawati; Arulita Ika Fibriana; Udin Bahrudin; Dian Widyaningrum; Syed Mohamed Aljunid
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.